Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide plus insulin glargine in type 2 diabetes uncontrolled on premixed insulin
ChiCTR2100041657Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lixisenatide and insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Peking University First Hospital. Primary endpoint: Change in HbA1c from baseline to 3 months. Started Dec 2020; status: recruiting.
02
Drugs
lixisenatideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100041657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041657.